Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.

Oncotarget - 24 May 2016

Mazor Ronit, Onda Masanori, Park Dong, Addissie Selamawit, Xiang Laiman, Zhang Jingli, Hassan Raffit, Pastan Ira

Abstract excerpt

Recombinant immunotoxins (RITs) are genetically engineered proteins being developed to treat cancer. They are composed of an Fv that targets a cancer antigen and a portion of a protein toxin. Their clinical success is limited by their immunogenicity. Our goal is to produce a new RIT that targets mesothelin and is non-immunogenic by combining mutations that decrease B- and T-cell epitopes. Starting with an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptive Immunity
Share to Epitopes, B-Lymphocyte

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epitopes, T-Lymphocyte

Share to Exotoxins

Share to Immunotoxins

Share to Mesothelioma

Share to Mesothelioma, Malignant

Share to T-Lymphocytes, Helper-Inducer

Source

Open in PubMed Open full text

Identifiers

PMID: 27167198
DOI: 10.18632/oncotarget.9171
PMCID: PMC5058652

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.PMID 27167198Read ↗

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.Semantic proximity Read ↗

Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.Semantic proximity Read ↗

Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights.Semantic proximity Read ↗

MesothelinSemantic proximity Read ↗

Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examplesSemantic proximity Read ↗

Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.Semantic proximity Read ↗

A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.Semantic proximity Read ↗

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopesSemantic proximity Read ↗

Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.Semantic proximity Read ↗

A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumorsSemantic proximity Read ↗

Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.Semantic proximity Read ↗

Immunotoxins with decreased immunogenicity and improved activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.